Classifying anti-obesity drugs:
$\text{Sibutramine}$ -- SNRI; withdrawn (cardiovascular toxicity).
$\text{Fenfluramine}$ -- Serotonin releaser; banned (valvulopathy).
$\text{Metformin}$ -- Biguanide; not approved for obesity per se.
$\text{Liraglutide (3 mg)}$ -- GLP-1 receptor agonist; acts on hypothalamic neurons to reduce appetite and prolongs satiety by delaying gastric emptying. It is the only option listed with regulatory approval for chronic weight management.
Key point: Bupropion + naltrexone (Contrave) is another approved combination, but liraglutide is the answer here.
\[\boxed{\text{Liraglutide}}\]